AbbVie’s New Drug Milestone Fuels Hype Despite Insider Selling

AbbVie ( (ABBV) ) has been popular among investors this week. Here is a recap of the key news on this stock.

AbbVie has completed a Phase 1a trial of its experimental drug ABBV-142, testing single ascending doses in healthy adults, including Asian participants, via both intravenous infusion and subcutaneous injection. The quadruple-blinded, placebo-controlled study focused on safety, tolerability, pharmacokinetics and immunogenicity, and its completion signals that AbbVie is now analyzing data to decide whether to advance the asset.

For investors, this milestone slightly lowers early-stage development risk and adds to AbbVie’s pipeline story at a time when rivals like Amgen and Johnson & Johnson are also pushing new biologics. Analyst sentiment remains broadly constructive: BMO Capital’s Evan Seigerman reiterated a Buy with a $258 target, and Evercore ISI also rates the stock Buy, while Citi stays at Hold.

Fundamentals remain solid, with AbbVie reporting quarterly revenue of $16.62 billion and net profit of $1.82 billion, reversing a GAAP net loss of $22 million a year earlier. However, insider sentiment is negative, with 38 insiders net selling over the past quarter and SVP Controller David Ryan Purdue offloading shares worth about $1.22 million in March 2026, a factor cautious investors will watch alongside the promising pipeline and rising price targets.